Search

Linda M Pacioretty

from Brooktondale, NY
Age ~60
Get Report
Also known as:
Linda Y
Phone and address:
508 White Church Rd, Brooktondale, NY 14817
Connected to:
Kazimiera J Paciorek, 93Mark A Paciorek, 59Peter S Paciorek, 48Sharyn A Paciorek, 77Timothy E Paciorek, 41Carlos A Pacios, 68James P Pacios, 57Juliann S Paciotta, 58Maura A Paciotti, 43Christopher M Pacious, 39

Linda Pacioretty Phones & Addresses

  • 508 White Church Rd, Brooktondale, NY 14817
  • 30 Brown Rd, Ithaca, NY 14850 (607) 266-9492
  • 232 Linden Ave #5, Ithaca, NY 14850 (607) 277-4125
  • 830 Dexter St #1, Denver, CO 80220

Work

Company: Bionexus May 1997 Position: President and chief executive officer

Education

Degree: Doctorates, Doctor of Philosophy School / High School: Cornell University 1988 to 1993 Specialities: Physiology

Industries

Health, Wellness And Fitness

Resumes

Resumes

Linda Pacioretty Photo 1

President And Chief Executive Officer

View page
Location:
Ithaca, NY
Industry:
Health, Wellness And Fitness
Work:
Bionexus
President and Chief Executive Officer
Education:
Cornell University 1988 - 1993
Doctorates, Doctor of Philosophy, Physiology University of California, Davis 1986 - 1988
Master of Science, Masters, Physiology University of California, Davis 1982 - 1986
Bachelors, Bachelor of Science

Business Records

Name / Title
Company / Classification
Phones & Addresses
Linda Pacioretty
CEO
Bio Nexus Ltd
Pharmaceutical Preparations
30 Brown Rd, Ithaca, NY 14850
Website: bionxs.com
Linda Pacioretty
CEO
Bio Nexus Ltd
Pharmaceutical Preparation Mfg
30 Brown Rd, Ithaca, NY 14850
(607) 266-9492, (607) 266-9481
Linda Pacioretty
CEO
Bio Nexus Ltd
Pharmaceutical Preparations
30 Brown Rd, Ithaca, NY 14850
Website: bionxs.com

Publications

Us Patents

Oral Composition With Insulin-Like Activities And Methods Of Use

View page
US Patent:
6733793, May 11, 2004
Filed:
Jun 4, 2002
Appl. No.:
10/163254
Inventors:
Linda M. Pacioretty - Brooktondale NY
John G. Babish - Brooktondale NY
Assignee:
MetaProteomics, LLC - San Clemente CA
International Classification:
A61K 3324
US Classification:
424646, 514 2, 514 12, 514 21, 514440, 514547, 514556, 514561, 514578, 514866, 514904, 514905, 514909, 424725, 424780, 42419515, 42419516, 42419517, 426 2, 426 72, 426 74
Abstract:
An orally administered, novel dietary supplement or therapeutic composition capable of insulin-like activity in animals, preferably humans, is provided. Contained in the composition are therapeutically effective amounts of vanadyl sulfate, alpha-lipoic acid, taurine, and chromium carnitine. The composition is preferably orally administered on a daily basis for at least about 4 weeks and can be used by normal, healthy individuals as well as diabetics.

Methods For Determining The Activity Of Complex Mixtures

View page
US Patent:
6780596, Aug 24, 2004
Filed:
Sep 17, 1998
Appl. No.:
09/156741
Inventors:
John G. Babish - Brooktondale NY
Linda M. Pacioretty - Brooktondale NY
M. Lisa Lee - Dryden NY
Assignee:
Ashni Naturaceuticals, Inc. - Salt Lake City UT
International Classification:
G01N 3303
US Classification:
435 71, 435 72, 435 721, 435 723, 435 21, 435 28, 435 693, 435 703, 435410, 436512, 436513, 436516, 436517, 436518
Abstract:
According to the present invention, the biological or pharmacological activity of a test material like a plant or herbal material, an extract of a plant or herbal material, a natural or synthetic compound or some combination thereof, can be quantified by observing the pattern of structural changes induced in a eukaryotic cells proteins. These structural changes may be evidenced by protein phosphorylation, by protein-protein interactions and the like. The amount and nature of protein phosphorylation is qualitatively and quantitatively related to the in vitro concentration of biologically/pharmacologically active components to which the mammalian cells are exposed. Additionally, formation or loss of protein-protein complexes may be determined in whole cell homogenates through the use of non-denaturing electrophoresis and staining for proteins or protein phosphorylation. The present invention allows natural products to be formulated into nutritional supplements and pharmacological preparations of consistent biological/pharmacological activity without the need to identify any of the chemical constituents responsible for the biological or pharmacological response.

Combinations Of Sesquiterpene Lactones And Ditepene Triepoxide Lactones For Synergistic Inhibition Of Cyclooxygenase-2

View page
US Patent:
6908630, Jun 21, 2005
Filed:
Jul 31, 2001
Appl. No.:
09/919349
Inventors:
John G. Babish - Brooktondale NY, US
Terrence Howell - Dryden NY, US
Linda Pacioretty - Brooktondale NY, US
Assignee:
Metaproteomics, LLC - San Clemente CA
International Classification:
A61K035/78
A01N043/16
A01N043/08
US Classification:
424725, 514453, 514468
Abstract:
A novel formulation is provided that serves to inhibit the inflammatory response in animals. The formulation comprises, as a first component an effective amount of a diterpene triepoxide lactone species and an effective amount of a second component of a sesquiterpene lactone species or derivatives thereof, and provides synergistic anti-inflammatory effects in response to physical or chemical injury or abnormal immune stimulation due to a biological agent or unknown etiology.

Curcuminoid Compositions Exhibiting Synergistic Inhibition Of The Expression And/Or Activity Of Cyclooxygenase-2

View page
US Patent:
6979470, Dec 27, 2005
Filed:
Jul 16, 2002
Appl. No.:
10/198277
Inventors:
John G. Babish - Brooktondale NY, US
Terrence Howell - Dryden NY, US
Linda Pacioretty - Brooktondale NY, US
Assignee:
Metaproteomics, LLC - San Clemente CA
International Classification:
A61K035/78
US Classification:
424756, 424725, 435189, 514461, 514679, 514763
Abstract:
Compositions comprising an effective amount of a curcuminoid species and an effective amount of a diterpene lactone species, a triterpene species or derivatives thereof that have a synergistic effect on specific inhibition of inducible COX-2 activity and have minimal effect on COX-1 activity are disclosed. Methods of using the compositions for providing synergistic anti-inflammatory effects are also disclosed.

Curcuminoid Compositions Exhibiting Synergistic Inhibition Of The Expression And/Or Activity Of Cyclooxygenase-2

View page
US Patent:
7279185, Oct 9, 2007
Filed:
Nov 13, 2004
Appl. No.:
10/988393
Inventors:
John G. Babish - Brooktondale NY, US
Terrence M. Howell - Freeville NY, US
Linda M. Pacioretty - Brooktondale NY, US
Assignee:
Metaproteonics, LLC - San Clemente CA
International Classification:
A01N 65/00
US Classification:
424725
Abstract:
A novel formulation is provided that serves to inhibit the inflammatory response in animals. The formulation comprises, as a first component an effective amount of a curcuminoid species and an effective amount of a second component selected from the group consisting of an alpha-acid species or a beta-acid species or derivatives thereof. The composition provides synergistic anti-inflammatory effects in response to physical or chemical injury or abnormal immune stimulation due to a biological agent or unknown etiology.

Curcuminoid Compositions Exhibiting Synergistic Inhibition Of The Expression And/Or Activity Of Cyclooxygenase-2

View page
US Patent:
7682636, Mar 23, 2010
Filed:
Feb 2, 2007
Appl. No.:
11/701583
Inventors:
John G. Babish - Brooktondale NY, US
Terrence M. Howell - Lansing NY, US
Linda M. Pacioretty - Brooktondale NY, US
Assignee:
Metaproteomics, LLC - San Clemente CA
International Classification:
A01N 65/00
US Classification:
424725
Abstract:
A novel formulation is provided that serves to inhibit the inflammatory response in animals. The formulation comprises, as a first component an effective amount of a curcuminoid species and an effective amount of a second component selected from the group consisting of an alpha-acid species or a beta-acid species or derivatives thereof. The composition provides synergistic anti-inflammatory effects in response to physical or chemical injury or abnormal immune stimulation due to a biological agent or unknown etiology.

Xanthohumol And Tetrahydro-Isoalpha Acid Based Protein Kinase Modulation Cancer Treatment

View page
US Patent:
7736677, Jun 15, 2010
Filed:
Jun 20, 2007
Appl. No.:
11/820568
Inventors:
Matthew L. Tripp - Gig Harbor WA, US
John G. Babish - Brooktondale NY, US
Jeffrey S. Bland - Fox Island WA, US
Veera Konda - Gig Harbor WA, US
Amy Hall - Gig Harbor WA, US
Linda M. Pacioretty - Brooktondale NY, US
Anu Desai - Gig Harbor WA, US
Assignee:
Metaproteomics, LLC - San Clemente CA
International Classification:
A01N 65/00
US Classification:
424725
Abstract:
Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on xanthohumol or isoxantohumol, or tetrahydro-isoalpha acids commonly found in hops.

Compositions And Methods For The Treatment Of Hiv-Associated Fat Maldistribution And Hyperlipidemia

View page
US Patent:
8017651, Sep 13, 2011
Filed:
Oct 31, 2003
Appl. No.:
10/699195
Inventors:
Linda M. Pacioretty - Brooktondale NY, US
John G. Babish - Brooktondale NY, US
Assignee:
Bionexus, Ltd. - Ithaca NY
International Classification:
A01N 37/00
A01N 37/18
A61K 31/19
A61K 31/20
A61K 31/16
A61K 31/095
US Classification:
514557, 514558, 514613, 514625, 514706
Abstract:
Compositions for treating or preventing fat maldistribution or hyperlipidemia resulting from anti-retroviral treatment of HIV-1 infection are disclosed. The compositions contain a conjugated fatty acid or alcohol and at least one member selected from the group consisting of a thiol-containing compound and a bioavailable form of trivalent chromium. Methods of treating a subject suffering from HIV-associated fat maldistribution or hyperlipidemia by administering a composition that includes a conjugated fatty acid or conjugated fatty alcohol and at least one member selected from the group consisting of a thiol-containing compound and a bioavailable form of trivalent chromium are similarly provided.
Control profile
Linda M Pacioretty from Brooktondale, NY, age ~60 Get Report